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ABSTRACT
Introduction: Long-term medical conditions (LTCs)
cause reduced health-related quality of life and
considerable health service expenditure. Writing
therapy has potential to improve physical and mental
health in people with LTCs, but its effectiveness is not
established. This project aims to establish the clinical
and cost-effectiveness of therapeutic writing in LTCs by
systematic review and economic evaluation, and to
evaluate context and mechanisms by which it might
work, through realist synthesis.
Methods: Included are any comparative study of
therapeutic writing compared with no writing, waiting
list, attention control or placebo writing in patients with
any diagnosed LTCs that report at least one of the
following: relevant clinical outcomes; quality of life;
health service use; psychological, behavioural or social
functioning; adherence or adverse events. Searches will
be conducted in the main medical databases including
MEDLINE, EMBASE, PsycINFO, The Cochrane Library
and Science Citation Index. For the realist review,
further purposive and iterative searches through
snowballing techniques will be undertaken.
Inclusions, data extraction and quality assessment will
be in duplicate with disagreements resolved through
discussion. Quality assessment will include using
Grading of Recommendations Assessment,
Development and Evaluation (GRADE) criteria. Data
synthesis will be narrative and tabular with meta-
analysis where appropriate. De novo economic
modelling will be attempted in one clinical area if
sufficient evidence is available and performed
according to the National Institute for Health and Care
Excellence (NICE) reference case.
BACKGROUND
Therapeutic writing
Writing as a form of therapy to improve phys-
ical or mental health has a long history1 and
can take many formats including those from a
psychotherapeutic background such as thera-
peutic letter writing,2 speciﬁc controlled inter-
ventions such as emotional disclosure/
expressive writing,3 to more recent approaches
such as developmental creative writing4 and
other epistolary approaches such as blogging.5
Other forms of potentially therapeutic writing
include reﬂective diaries, free writing, short
stories, song writing, unsent letters and
memoirs. In addition, therapeutic writing
interventions might be delivered in different
contexts: as individual self-help therapy at
home, in a healthcare centre, as part of a pro-
gramme in a rehabilitation clinic or within a
group of people with similar or different
health conditions, in person or through the
world wide web. People engaging in thera-
peutic writing can either receive feedback
from a peer, from a healthcare professional,
from their writing group or receive no
feedback.6
With the development of UK organisations
such as LAPIDUS (Association for Literary
Arts in Personal Development) dedicated to
the promotion of therapeutic writing based
on the premise that it has health beneﬁts, it
is important to evaluate the effectiveness of a
variety of different approaches.
The most evaluated form of therapeutic
writing is the expressive writing intervention
as described by Pennebaker et al.3 7–9
Expressive writing is a technique whereby
people are encouraged to write (or talk into
a tape recorder) in private about a traumatic,
stressful or upsetting event, usually from
their recent or distant past. They write for
15–30 min typically for 3–4 days within a rela-
tively short time period such as consecutive
days or within 2 weeks. Participants are
encouraged to write about their deepest
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thoughts and feelings concerning an event or experi-
ence they have not talked about with others. The
control group may receive no treatment, or a written
exercise with a non-emotional topic or be on a waiting
list. Randomised controlled trials (RCTs) of expressive
writing have been conducted in a wide variety of partici-
pants including healthy students, people undergoing
psychological stressors, such as bereavement, or in
people with long-term medical conditions (LTCs), such
as rheumatoid arthritis and asthma.
Expressive writing is thought to be beneﬁcial for
longer term health effects and as such is now frequently
referred to in general psychology textbooks as a poten-
tially beneﬁcial intervention.10 However, some have
argued that this intervention is too brief to have any
long lasting effects.9 11 There has been remarkably little
critique published speciﬁcally on expressive writing.
Those within the ﬁeld of developmental creative
writing, however, consider that Pennebaker’s expressive
writing paradigm may be more a starting point in learn-
ing to release emotion through writing, but that added
beneﬁt may occur with more ‘free writing’ which could
allow for development and shaping of the material,
which leads to a ‘a new relationship with aspects of self-
experience’.4 It is this connection with a core sense of
self from which creative writing is said to derive beneﬁt.4
With newer forms of writing, such as blogging, associ-
ation with increased perceived social support has been
demonstrated.5 Given the importance of social support
to well-being, this suggests yet further mechanisms by
which writing in its various formats may improve health.
It is a popular assumption that creative writing helps
overcome life’s stresses, and some professional writers
have noted this. Notwithstanding the epistemological,
methodological and ethical challenges of studying the
impact of creative writing on mental health, it seems
appropriate to evaluate whether the wider ﬁeld of thera-
peutic writing might help with mental and physical
LTCs.
There have been several systematic reviews and
meta-analyses on emotional disclosure/expressive
writing, one of which was undertaken by our own
team.8 12–15 The Cochrane Library lists a protocol for
evaluation of written emotional disclosure for asthma.16
Our preliminary scoping searches did not ﬁnd any previ-
ous economic evaluations of any forms of therapeutic
writing. None of the systematic reviews or meta-analyses
incorporates a qualitative systematic review or a realist
review to make sense of how and why therapeutic
writing might work.
Long-term medical conditions
The prevalence of LTCs increases with ageing popula-
tions. In 2002, the leading chronic diseases (cardiovascu-
lar disease, cancer, chronic respiratory disease and
diabetes) were responsible for 29 million deaths world-
wide.17 According to the UK Department of Health
(DoH),18 more than 15 million people in England
(including half of all those aged over 60 years) are living
with at least one LTC, and the risk of death is particu-
larly high in those with three or more conditions occur-
ring concurrently.19 LTCs also result in a huge burden
on National Health Service (NHS) resources. Although
some are preventable, for most LTCs continuing care is
the only realistic management strategy, as biological and
psychosocial mechanisms regulating disease progression
are not yet fully understood. Since LTCs are difﬁcult to
improve, especially for elderly populations, healthcare
programmes such as self-management support and
patient education, often combined with structured clin-
ical follow-up, have been suggested as a way to improve
the quality of life of such patients.20 New therapeutic
approaches may help to extend the lifespan and quality
of life in people with LTCs.
Realist reviews
These reviews ask ‘what works for whom in what circum-
stances?’ and consider the interaction between context,
mechanism and outcome (CMO), that is, how particular
contexts have ‘triggered’ (or, conversely, interfered with)
mechanisms to generate the observed outcomes.21 The
philosophical basis is realism, which assumes the exist-
ence of an external reality (a ‘real world’) but one that
is ‘ﬁltered’ (ie, perceived, interpreted and responded
to) through human senses, volitions, language and
culture. Such human processing initiates a constant
process of self-generated change in all social intuitions,
a vital process that has to be accommodated in evaluat-
ing social programmes.
In order to understand how outcomes are generated,
the roles of external reality and human understanding
and response need to be incorporated. Realism does
this through the concept of mechanisms, whose precise
deﬁnition is contested but for which a working deﬁn-
ition is “underlying entities, processes or structures
which operate in particular contexts to generate out-
comes of interest.”22 Different contexts interact with dif-
ferent mechanisms to make particular outcomes more
or less likely—hence a realist review produces recom-
mendations of the general format “In situations [X],
complex intervention [Y], modiﬁed in this way and
taking account of these contingencies, may be appropri-
ate.” This approach, when performed well, is widely
recognised as a robust methodology which is particularly
appropriate when seeking to explore the interaction
between CMO in a complex intervention (see eg,
Berwick’s editorial in JAMA explaining why experimental
(RCT/meta-analysis) designs may need to be supple-
mented (or perhaps in some circumstances replaced) by
realist studies aimed at elucidating CMO conﬁgurations
(CMOCs)).23
A realist approach is particularly useful for this project
because therapeutic writing is a complex intervention
which could be useful in a variety of patient groups and
currently it is unclear whether it is effective for all or
some, and how and why it might be effective.
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Objectives of the project
1. What are the different types of therapeutic writing
that have been evaluated in comparative studies?
What are their deﬁning characteristics? How are they
delivered? What underlying theories have been pro-
posed for their effect/s?
2. What is the clinical effectiveness of the different
types of therapeutic writing for LTCs compared with
no writing or other suitable comparators?
3. How is heterogeneity in results of empirical studies
accounted for in terms of patient and/or contextual
factors, and what are the mechanisms and modera-
tors responsible for the success, failure or partial
success of interventions (ie, what works for whom in
what circumstances and why)?
4. What is the cost-effectiveness of one or more types of
therapeutic writing in one or more representative
LTCs where there is sufﬁcient information on the
intervention, comparator and outcomes to conduct
an economic evaluation.
RESEARCH METHODS
Systematic review of effectiveness and realist review
We will undertake two interlinked reviews simultaneously
(see table 1 for inclusion criteria). No language restric-
tions will be applied.
Search strategy
The searches inform both reviews, ﬁnd any previous
models that have been conducted in therapeutic writing
and provide some inputs to the decision-analytic model.
A database of published and unpublished literature will
be assembled from searches using a comprehensive
search strategy, examination of reference lists in system-
atic reviews, hand searching journals and contact with
experts in the area. The wider searches will map the
extent of relevant literature (mapping review). From this
list of studies, appropriately includable studies for the
systematic review will be selected, according to the inclu-
sion criteria in table 1.
The following databases will be searched: MEDLINE,
EMBASE, PsycINFO, CAB Abstracts, PEDro, PILOTS,
Zetoc, Science Citation Index, Social Sciences Citation
Index, Linguistics and Language Behavior Abstracts,
Periodicals Index Online, Applied Social Sciences Index
and Abstracts (ASSIA), ERIC, AMED, CINAHL,
Cochrane Central Register of Controlled Trials
(CENTRAL) and Database of Abstracts of Reviews of
Effects (DARE) for primary studies. Grey literature
searching is important because of the possibility that
effect size estimates may have been overestimated due to
selective reporting bias and unpublished studies are
known to be less likely to have statistically signiﬁcant
results compared with published studies.24 Information
on studies in progress and unpublished research or
research reported in the grey literature will be sought by
searching a range of relevant databases including the
Inside Conferences, Systems for Information in Grey
Literature (OpenSIGLE), Dissertation Abstracts, Current
Controlled Trials database and Clinical Trials.gov.
Cochrane Database of Systematic Reviews (CDSR),
Health Technology Assessment Database (HTA) and the
Campbell Library will be searched for systematic reviews
and economic evaluations. In addition, Internet
searches will also be carried out using specialist search
gateways (such as OMNI: http://www.omni.ac.uk/),
general search engines (such as Google: http://www.
Table 1 Review question components
Question
components
Systematic review
Inclusion criteria Exclusion criteria
Population Any LTC as per DoH definition18 Acute conditions, stress, bereavement etc
Exposure/
intervention
Any form of therapeutic writing including emotional
disclosure/expressive writing, poetry, diaries, etc
Talking to a listener, counselling, psychotherapy,
talking into a tape recorder, mobile phone or similar
where this is the primary mode of delivering the
intervention, expressive drama, dance, film-making.
Evaluation of other people’s writing
Comparison Non-writing, waiting list, inexpressive writing,
attention controls and any control thought to be
inactive
Any active or possibly active control including
therapeutic writing
Outcome Any relevant clinical outcomes including
disease-specific outcomes and generic outcomes
such as: quality of life, health service use,
psychological outcomes, behavioural outcomes,
social functioning, adverse events, adherence to
therapies and costs
Intermediate physiological outcomes such as
salivary cortisol, immune parameters not routinely
measured in the management of LTCs
No reporting of numerical results for each group
Study designs Any comparative studies including RCTs, cohort or
case–control studies. Economic evaluations
Single case reports, case series, studies where
results for intervention and control groups are not
presented separately
DoH, Department of Health; LTC, long-term medical condition; RCTs, randomised controlled trials.
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google.co.uk/) and metasearch engines (such as
Copernic: http://www.copernic.com/).
Citations will be selected for inclusion in each review
in a two-stage process using the criteria in table 1 by one
reviewer with a random 10% of citations independently
checked by a second reviewer. Copies of full manuscripts
of all citations that are likely to meet the selection cri-
teria will be obtained. Two reviewers will then independ-
ently select studies that meet the predeﬁned criteria.
Disagreements will be resolved by consensus and/or
arbitration involving a third reviewer. Authors of confer-
ence abstracts will be contacted for fully published arti-
cles. If an abstract only is available, results will be in an
appendix. Once the ﬁnal sample for the systematic
review has been identiﬁed, each paper will be tracked in
Science Citation Index and titles screened independ-
ently to identify sister papers of these documents.
Definition of LTCs
There is no deﬁnitive list of LTCs and the potential
range of diseases of interest is extensive and diverse. For
the purposes of this review, we will adopt the UK DoH
deﬁnition of an LTC: “Long term conditions are those
conditions that cannot, at present, be cured, but can be
controlled by medication and other therapies. They
include diabetes, asthma and chronic obstructive pul-
monary disease.” Our working deﬁnition of LTCs also
includes mental health problems, including eating disor-
ders, and chronic infections such as HIV. All cancer
studies will be included because previous reviewing
experience has shown that patients may receive palliative
care for prolonged periods and terminally ill patients in
hospices may still be receiving active treatment. Thus the
distinction between active treatment and palliation may
become difﬁcult to distinguish and furthermore disease
trajectories are not always predictable. There is a debate
around whether obesity in the absence of any comorbid-
ity is a disease25 and we will exclude studies in people
with uncomplicated overweight and obesity. We will also
evaluate addictive conditions (alcohol, smoking, illegal
drugs and legal drugs) and learning disability because
the results would be useful to the NHS, although these
may not meet the current deﬁnition of LTCs. We have
excluded the following:
▸ Personality traits such as alexithymia, body
dissatisfaction.
▸ People who have undergone stressful life events such
as bereavement, domestic violence and child sex
abuse.
▸ People found to be at increased risk of developing an
LTC.
Systematic review of effectiveness
Studies’ ﬁndings will be extracted in duplicate using pre-
designed and piloted data extraction forms, based on
those previously developed. Any disagreements will be
resolved by consensus and/or arbitration involving a
third reviewer. Missing information will be obtained
from investigators if it is crucial to subsequent analysis.
To avoid introducing bias, unpublished information will
be coded in the same fashion as published information.
In addition to using multiple coders to ensure the repro-
ducibility of the overview, sensitivity analyses around
important or questionable judgements regarding the
inclusion or exclusion of studies, the validity assessments
and data extraction will be performed.
Quality of selected studies will be assessed based on
accepted contemporary standards such as the Newcastle
Ottawa scale for cohort and case–control studies26 and
Grading of Recommendations Assessment, Development
and Evaluation (GRADE). The GRADE methodology27–29
will guide us when assessing the quality of the evidence
overall and summarising the results.30 31
Meta-analyses will be conducted using standard soft-
ware packages such as STATA. A special problem that we
are likely to face is very little RCT evidence, which is why
observational studies will be included for some types of
interventions. Separate analyses will be performed on
randomised and non-randomised data. Any heterogen-
eity of results between studies will be statistically assessed
using I2 and graphically assessed, including use of funnel
plots. We will explore causes of the heterogeneity and
proceed to perform meta-analysis if appropriate.31 To
explore causes of heterogeneity, subgroup analyses will
be planned a priori to see whether variations in clinical
factors, for example, populations, interventions, out-
comes or study quality, affect the estimation of effects.
Individual factors explaining heterogeneity will also be
analysed using meta-regression, to determine their
unique contribution to the heterogeneity, if possible.32
Conclusions regarding the typical estimate of an effect
size of the intervention will be interpreted cautiously if
there is signiﬁcant heterogeneity. If necessary, we will use
indirect comparisons to inform the economic model.
Health economic evaluation
This is a broad term to describe a variety of approaches
that can be used to illustrate the economic conse-
quences of a therapeutic strategy. In a project such as
this, it is important to be ﬂexible with regard to plan-
ning an economic evaluation because the depth of com-
plexity of any economic modelling, for example, will be
driven partially by the data available. If no health-related
quality of life information is found, it may not be appro-
priate to state in advance that a cost utility analysis will
be conducted. However, value for money is an important
consideration in the current economic climate. So any
information on costs and cost-effectiveness compared
with an appropriate comparator will be presented. If any
economic evaluations were found, they will be evaluated
for quality using the National Institute for Health and
Care Excellence (NICE) reference case and for publica-
tion standards using Consolidated Health Economic
Evaluation Reporting Standards statement.33
If there are well-powered RCTs with homogeneous
outcomes in the same disease area or areas, we will then
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associate improvements in outcomes with gains in
health-related quality of life where possible. This may
include use of decision-analytic modelling either by
using an existing disease-speciﬁc model available in the
literature or by constructing a de novo model. The aim
will be to estimate the incremental cost-effectiveness of
incorporating therapeutic writing into the currently
recommended NHS treatment regimen for the particu-
lar disease area. Results will be presented in terms of
cost per quality-adjusted life year (QALY) gained, with
the uncertainty in both the RCT evidence and the mod-
elling incorporated. If the information in the literature
found in the systematic review is not sufﬁcient, then we
will carry out more general forms of economic evalu-
ation such as cost-consequences or cost-minimisation
analyses. All economic evaluations will follow the refer-
ence case used by the NICE as far as the available evi-
dence permits, for example, discounting costs and
beneﬁts at 3% per annum, and using the perspective of
the NHS and social services.
The economic modelling component of the work is
likely to be challenging. Some of these challenges
are likely to include the following: (1) the intervention
is likely to affect a wide range of disease areas and clin-
ical outcomes, which cannot be captured in a single
disease model; (2) there may be a need to combine evi-
dence, that is, heterogeneous in terms of quality
(mixture of observational studies, trials and qualitative
studies) as well as the nature of the intervention and
population studied and (3) there may not be sufﬁcient
disease natural history and quality of life information in
the literature to conduct a cost-utility analysis to the spe-
ciﬁcations of the NICE reference case.
To address these challenges, we have deliberately left
the precise nature of the health economic evaluation
open ended until after the literature reviews are com-
pleted. Whenever possible, we will conduct a ‘gold stand-
ard’ cost-utility analysis, using a decision analytic model
to examine the impact of the intervention on disease
progression, with its parameters informed by a synthesis
of the highest quality RCT evidence, and with outcomes
presented in terms of costs per QALY. However, we envi-
sion that the opportunities for this kind of analysis are
likely to be slim. In most cases, we will make the most of
any evidence available, for instance conducting cost-
consequences analyses if there is no quality of life infor-
mation or if there are a range of different outcomes that
cannot be captured within a single model. Such analyses
will still provide useful information to guide decision-
making, and will also highlight the gaps in evidence that
can be addressed by future studies.
Realist review
The realist review will cover the articles in the above
sampling frame (table 1) along with ‘sister papers’ that
is, any qualitative or mixed-method studies linked to
these index papers, but published as a separate paper.
The review team will begin by attempting to develop a
‘generic’ initial programme theory for therapeutic
writing. That is, to build a model that tries to explain
how therapeutic writing is meant to go about producing
its potential beneﬁts. When analysing the ﬁndings from
the effectiveness review, we will use interpretive cross-
case comparison to understand and explain how and
why observed outcomes have occurred in the studies
included in our review. In other words we will compare
interventions where therapeutic writing has been ‘suc-
cessful’ against those which have not; to try to under-
stand how the context has (or has not) inﬂuenced the
reported ﬁndings. Speciﬁcally, when analysing the ﬁnd-
ings from the effectiveness review, we will be using a
realist logic that seeks to construct CMOCs for the ﬁnd-
ings in the ‘successful’ and ‘less successful’ therapeutic
writing interventions. The purpose of this process is to
construct for each ﬁnding (outcome) an explanation of
what has caused the outcome to occur (mechanism)
and the conditions (context) that have triggered this
putative mechanism. If necessary, we will seek to itera-
tively develop one or more explanatory theories to
account for these CMOCs. An important process is to
build an understanding of how the CMOCs we have con-
structed ﬁt in with our initial programme theory. In
other words, for any one CMOC, how does it (if at all)
explain how therapeutic writing is meant to go about
producing its potential beneﬁts? For example, does the
CMOCs tell us anything about how we might need to
reﬁne our initial programme theory? Thus throughout
the realist review, we move iteratively between the ana-
lysis of particular examples, a reﬁnement of the over-
arching programme theory and (if necessary) further
iterative searching for data to test particular theories or
subtheories. The pursuit of rigour in realist research
reﬂects principles usually seen in qualitative research,
although it may draw on qualitative, quantitative or
mixed methods. Much rests on achieving immersion (ie,
reading and re-reading papers to really understand what
was done and why), thinking reﬂexively about ﬁndings,
developing theory iteratively as emerging data are ana-
lysed, seeking disconﬁrming cases and alternative expla-
nations, and defending one’s interpretations to
researchers within and outside one’s own team.34
Two coapplicants (TG and GW) have recently led an
international project, the RAMESES study, which has
developed guidance for realist review. This involved a sys-
tematically recruited group of international experts who
have produced methodological guidance and publica-
tion standards (http://www.ramesesproject.org). We will
ensure that the new RAMESES standards (which we
anticipate will become the gold standard for realist
review internationally) are strictly followed in the realist
component of this study.
Narrative synthesis of systematic review of effectiveness,
realist review and health economic evaluation
There are two published examples of combining con-
ventional systematic review methods with realist review
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methods. One addressed the question “What is the
impact of school feeding programmes on growth and
educational achievement in deprived children, and what
explains variation in the ﬁndings across studies?”35 36
The other addressed the question “What are the compo-
nents and statistical properties of different risk scores for
type 2 diabetes, and what explains whether and how
these scores were used?”34 This review considered longitu-
dinal and cross-sectional population cohort studies and
papers describing case studies of attempts to implement
the risk score. The therapeutic writing will use a similar
approach to these two projects, using joining text and
commentary (‘narrative synthesis’). This ‘narrative
summary’ or ‘narrative synthesis’ is a very well established
and robust way of linking two sets of review ﬁndings, espe-
cially when those sets of ﬁndings are philosophically
incommensurable and/or address different research ques-
tions within a single study (hence do not lend themselves
to a ‘technical’ approach to combining ﬁndings).37 38
We will also be integrating the results of the economic
evaluation with the realist and conventional systematic
reviews. Combining economic evaluation with systematic
reviews is very commonly done for HTA reports, so needs
no further explanation here. However, what is frequently
not discussed is how the clinical context is combined with
the economic evaluation to enable the HTA report to have
clinical credibility. This is frequently done by ensuring that
the clinicians on the project are present when discussing
the economic model, fully understand it and can appreci-
ate the implications of the assumptions made. Their
insights into the patient experience often result in the
structure of the model needing to be changed, or different
numerical inputs being used to reﬂect clinical reality. In
our project we will be fully involving patient representatives
and therapeutic writing experts in all aspects of the project.
The reviews are currently underway and this 18-month
project will be complete in summer 2014 (see ﬁgure 1—
Gantt chart) with peer reviewed results available by the
end of 2014.
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